AGL

EX-99.1

2 agl-20260331xexx991.htm

EX-99.1

Document

Exhibit 99.1

agilon health Reports First Quarter 2026 Results

Raises Full-Year 2026 Total Revenues, Medical Margin and Adjusted EBITDA Guidance

Westerville, O.H., May 6, 2026 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarter ended March 31, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.

“Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We are seeing early returns from investments in data and technology, clinical execution, and operating discipline,” said Ronald A. Williams, Executive Chairman. “We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion. We remain confident in our 2026 outlook and long-term growth trajectory.”

Mr. Williams added, “We are also excited to welcome Tim O’Rourke as CEO, who brings more than 25 years of healthcare leadership. Under Tim’s leadership we expect to further sharpen our focus on execution with faster pull through from action to outcome and deliver increased value for all stakeholders.”

First Quarter 2026 Results:

•Total members on the agilon platform decreased to 536,000 as of March 31, 2026, including 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries. Year-over-year changes to membership primarily reflect previously disclosed market exits, as well as payor exits in certain markets resulting from a disciplined approach to contracting focused on profitability.

•Total revenue of $1.42 billion in the first quarter 2026 decreased 7% compared to $1.53 billion in the first quarter 2025. Revenue reflects lower year-over-year membership partially offset by improved pricing, contract economics and burden of illness performance.

•Gross profit was $65 million in the first quarter 2026 compared to $51 million in the first quarter 2025. Net income was $49 million in the first quarter 2026 compared to $12 million in the first quarter 2025.

•Medical margin was $149 million during the first quarter 2026, compared to $128 million in the first quarter 2025. Medical margin includes cost trend for Medicare Advantage members reserved at 7.4%.

•Adjusted EBITDA was $54 million in the first quarter 2026 compared to $21 million in the first quarter 2025. Reflects the aforementioned items and strong ACO REACH performance.

Key Financial and Operating Metrics ($M):

(First Quarter 2026 vs. 2025)

Three Months

Ended March 31,

Change

20262025% YoY

Medicare Advantage Members1 426,000491,000(13%)

ACO Model Members1,2 110,000114,000(4%)

Total Members Live on Platform1,2 536,000605,000(11%)

Avg. Medicare Advantage Members424,000490,000(13%)

Total Revenues $1,420$1,533(7%)

Gross Profit (Loss)$65$5128%

Medical Margin$149$12816%

Net Income (Loss) $49$12NM

Adjusted EBITDA3 $54$21162%

Geography Entry Costs $2$5(60%)

1.Membership metrics reflect end of period results.

2.agilon’s ACO model entities are not included within its consolidated financial results.

3.agilon’s ACO model entities contributed $27 million and $20 million to Adjusted EBITDA during the first quarter 2026 and first quarter 2025, respectively.

Capital Position and Balance Sheet

agilon health’s balance sheet as of March 31, 2026 included cash, cash equivalents and marketable securities of $303 million and total debt of $32 million. At the end of the quarter, agilon health had $47 million of cash associated with the Company’s unconsolidated ACO model entities.

Second Quarter and Revised Fiscal Year 2026 Guidance and Assumptions

Guidance for Fiscal Year 2026 ($M):

Year Ended December 31, 2026

Updated GuidancePrevious Guidance

LowHighLowHigh

Medicare Advantage Members1

425,000435,000N/AN/A

ACO REACH Members1,2

100,000105,000N/AN/A

Total Members Live on Platform1

525,000540,000N/AN/A

Avg. Medicare Advantage Members430,000437,000N/AN/A

Total Revenues$5,680$5,805$5,410$5,580

Medical Margin $350$400$300$350

Adjusted EBITDA3 $10$40($15)$15

Geography Entry Costs4

$15$15N/AN/A

1.Membership reflects management’s outlook for end of period.

2.agilon’s partnered ACO model entities are not consolidated within its financial results.

3.Adjusted EBITDA contribution from ACO model entities is expected to be approximately $25-$30 million for fiscal year 2026.

4.Geography Entry Costs represent the corresponding expense included in the low-end and high-end of management’s outlook for Adjusted EBITDA.

Guidance for Second Quarter 2026 ($M):

Quarter Ended

June 30, 2026

LowHigh

Medicare Advantage Members1 434,000444,000

ACO REACH Members1,2 106,000109,000

Total Members Live on Platform1 540,000553,000

Avg. M

agl-202602250001831097FALSE00018310972026-02-252026-02-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026

agilon health, inc. (Exact name of Registrant as Specified in Its Charter)

Delaware001-4033237-1915147 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)

440 Polaris Parkway, Suite 550

Westerville, Ohio 43082 (Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: 562 256-3800 Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common stock, par value $0.01 per shareAGLThe New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and twelve months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure. On February 25, 2026, the Company issued an investor presentation regarding the Company’s financial results for the three and twelve months ended December 31, 2025. A copy of the investor presentation is furnished herewith as Exhibit 99.2. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and the related information in Exhibits 99.1 and 99.2 attached hereto is being furnished herewith, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference therein.

Item 9.01 Financial Statements and Exhibits. (d)Exhibits

Exhibit Number Description

99.1Press Release dated February 25, 2026.

99.2Investor Presentation dated February 25, 2026.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

agilon health, inc.

Date:February 25, 2026By: /s/ JEFFREY SCHWANEKE Jeffrey Schwaneke Chief Financial Officer

agl-202511040001831097FALSE00018310972025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025

agilon health, inc. (Exact name of Registrant as Specified in Its Charter)

Delaware001-4033237-1915147 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)

440 Polaris Parkway, Suite 550

Westerville, Ohio 43082 (Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: 562 256-3800 Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common stock, par value $0.01 per shareAGLThe New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, agilon health, inc. (the “Company”), a Delaware corporation, issued a press release setting forth its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure. On November 4, 2025, the Company issued an investor presentation regarding the Company’s financial results for the three and nine months ended September 30, 2025. A copy of the investor presentation is furnished herewith as Exhibit 99.3. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and the related information in Exhibits 99.1 and 99.2 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference therein.

Item 9.01 Financial Statements and Exhibits. (d)Exhibits

Exhibit Number Description

99.1Press Release dated November 4, 2025.

99.2Investor Presentation dated November 4, 2025.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

agilon health, inc.

Date:November 4, 2025By: /s/ JEFFREY SCHWANEKE Jeffrey Schwaneke Chief Financial Officer